A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

Phase 1

Genentech, Inc.

Bevacizumab